Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 5
1997 3
1999 6
2000 6
2001 3
2002 2
2003 4
2006 1
2007 1
2008 1
2013 2
2014 2
2016 4
2017 2
2020 2
2023 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, Lanini S, Colavita F, Notari S, Oliva A, Meschi S, Casetti R, Mondillo V, Vergori A, Bettini A, Grassi G, Pinnetti C, Lapa D, Tartaglia E, Gallì P, Mondi A, Montagnari G, Gagliardini R, Nicastri E, Lichtner M, Sarmati L, Tamburrini E, Mastroianni C, Stingone C, Siddu A, Barca A, Fontana C, Agrati C, Girardi E, Vaia F, Maggi F, Antinori A; Mpox Vaccine Lazio Study Group. Mazzotta V, et al. Among authors: lepri ac. EClinicalMedicine. 2024 Jan 12;68:102420. doi: 10.1016/j.eclinm.2023.102420. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38292040 Free PMC article.
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
Matusali G, Vergori A, Cimini E, Mariotti D, Mazzotta V, Lepri AC, Colavita F, Gagliardini R, Notari S, Meschi S, Fusto M, Tartaglia E, Girardi E, Maggi F, Antinori A; HIV‐VAC Study Group. Matusali G, et al. Among authors: lepri ac. J Med Virol. 2024 Apr;96(4):e29598. doi: 10.1002/jmv.29598. J Med Virol. 2024. PMID: 38624044
Incidence and predictors of clinical failure after early treatment for mild-to-moderate COVID-19 in high-risk individuals: A multicentric cohort study.
Mastrorosa I, Lepri AC, Borgo CD, Rosati S, Rueca M, Sarmati L, Mastroianni C, Fantoni M, Maggi F, Nicastri E, Girardi E, Lichtner M, Antinori A, Mazzotta V; Early Treatment for COVID‐19 Lazio Study Group. Mastrorosa I, et al. Among authors: lepri ac. J Intern Med. 2025 Mar;297(3):328-334. doi: 10.1111/joim.20030. Epub 2024 Nov 13. J Intern Med. 2025. PMID: 39537383 Free PMC article.
Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Vergori A, Matusali G, Lepri AC, Cimini E, Fusto M, Colavita F, Gagliardini R, Notari S, Mazzotta V, Mariotti D, Cicalini S, Girardi E, Vaia F, Maggi F, Antinori A; HIV-VAC Study group. Vergori A, et al. Among authors: lepri ac. Int J Infect Dis. 2023 Sep;134:195-199. doi: 10.1016/j.ijid.2023.06.010. Epub 2023 Jun 19. Int J Infect Dis. 2023. PMID: 37343783 Free PMC article.
49 results